Cardiomyopathy

Claims data show a 4- to 6-fold increase in ATTR-CM diagnoses, with a growing comorbidity burden before diagnosis.

Aficamten improved exercise capacity across submaximal, peak, and recovery measures.

A pooled nonrandomized trial of AAVrh.10hFXN across 17 patients showed reduced LVMI and lower high-sensitivity troponin I levels at all 3 dose cohorts.

Acoramidis treatment sustained reductions in all-cause mortality, cardiovascular mortality, and first cardiovascular hospitalization through 54 months.

A prospective registry study suggests cardiac MRI scar burden and biomarkers may refine prognostic assessment beyond current sudden cardiac death models.

RBM20 truncating variants are associated with a milder, lower-penetrance form of dilated cardiomyopathy compared with other pathogenic genetic drive.

Researchers found persistent and substantial delays between heart failure diagnosis and ATTR-CM identification.

A recent study identified persistent myocardial fibroblast activation in patients with heart failure with reduced ejection fraction, with distinct patterns by etiology.

A large cohort study across UK Biobank and All of Us finds RBM20 variants contribute to arrhythmogenic dilated cardiomyopathy.

Cardiac MRI tissue characterization can detect early, low-burden transthyretin cardiac amyloidosis and accurately distinguish it from similar conditions, a study found.

Vutrisiran not only slowed progression to advanced heart failure in patients with ATTR-CM but also reduced mortality and MACE among those who developed advanced disease.

Vutrisiran kept a favorable safety profile in patients with transthyretin amyloidosis treated for up to 58 months, with AE rates comparable to placebo and no new safety concerns.

A Cleveland Clinic study shows a medically trained AI system can rapidly screen electronic health records to identify eligible participants for rare disease clinical trials.

Patients with oHCM experience significant variation in cardiovascular events, health care resource use, and costs across age, sex, race, and US region.

A new Mayo Clinic study questions the benefit of implantable cardioverter-defibrillator use to treat patients with transthyretin cardiac amyloidosis.

Meaningful reductions in all-cause mortality and cardiovascular hospitalizations modeled benefits compared with untreated populations.

Experts propose a 6-parameter framework for ATTR-CM monitoring and disease progression in transthyretin amyloid cardiomyopathy.

Vutrisiran significantly reduces mortality and cardiovascular events in older patients with ATTR-CM, enhancing quality of life and functional capacity.

Adults with hypertrophic cardiomyopathy living in lower-income or more socially deprived areas experienced significantly higher risks of heart failure, arrhythmias, stroke, and death.

Adults with hypertension who have prediabetes and subclinical myocardial injury or stress face a higher risk of incident heart failure, a study suggests.

Among patients who did receive early DNAR orders, survival to hospital discharge did not differ by race or ethnicity.

The cardiac myosin inhibitor is expected to be available in the US in the second half of January 2026.

Genetics played a major role in predicting worsening LVEF, progressing to a dilated cardiomyopathy phenotype, and a combined end point of both.

Intranasal etripamil was approved to self-treat episodes of paroxysmal supraventricular tachycardia, supported by phase 3 RAPID trial data.